 12. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of sunitinib andor propranolol e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection. 